Application of hemoglobin in preparation of medicine for treating bone destruction diseases
By using hemocyanin to inhibit the RANKL/RANK pathway and regulate osteoclast activity, it was formulated into a drug to treat alcoholic avascular necrosis of the femoral head, solving the problem of bone resorption and formation imbalance in bone destruction diseases, and reducing the medical cost and complications of prosthesis replacement.
Patent Information
- Application Number
- CN202411118628.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies have failed to effectively address bone destruction caused by alcoholic avascular necrosis of the femoral head, particularly the imbalance between bone resorption and formation due to a decrease in osteoblasts and an increase in osteoclast activity within the bone tissue, leading to chronic degenerative diseases. Furthermore, prosthesis replacement presents challenges related to medical costs and complications.
Using hemosiderin as the active ingredient, it regulates osteoclast activity and bone resorption by inhibiting the RANKL/RANK pathway. It is then combined with pharmaceutically acceptable salts or excipients to prepare tablets, capsules, or injections for the treatment of bone destructive diseases.
Hemococcus significantly inhibits osteoclast proliferation and differentiation, improves bone resorption, has anti-inflammatory effects, improves symptoms of bone destruction diseases, and reduces the medical costs and risk of complications associated with prosthesis replacement.
Smart Images

Figure CN118924740A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medical applications, and in particular relates to an application of hemoglobin in the preparation of a medicine for treating bone destruction diseases. Background Art
[0002] Blood tube is a common medicinal plant used by the Tujia people. It is a plant of the Schisandra genus of the Schisandra family, Kadsuraheteroclita (Roxb) Craib. Its vine stems are often used as medicine. Blood tube is sweet, slightly spicy and warm in nature. It has the effects of nourishing blood and activating blood circulation, dispelling wind and dampness, promoting qi and relieving pain. It is commonly used by the Tujia people to treat rheumatic pain, epigastric pain, menstrual pain, bone pain, rheumatic arthritis, lumbar muscle strain, colds, postpartum paralysis and other symptoms. It is included in the 2005 edition of the Chinese Pharmacopoeia as "schisandra chinensis vine stems", which is one of the main ingredients of Zhonghua Dieda Pills and is used to treat traumatic injuries.
[0003] Schisanlactone E is a triterpenoid compound extracted from schisandra. Existing studies have shown that it has anti-tumor and anti-rheumatoid arthritis effects. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide an application of hemoglobin in the preparation of a medicine for treating bone destructive diseases.
[0005] The present invention provides an application of hemoglobin in preparing a medicine for treating bone destruction diseases.
[0006] Preferably, the bone destruction disease is alcoholic femoral head necrosis.
[0007] Alcoholic femoral head necrosis is a chronic degenerative disease characterized by reduced blood perfusion, ischemia and hypoxia in the femoral head, mainly caused by interruption of blood supply to the subchondral zone of the femoral head and the anterior and upper parts of the femoral head. 80% of patients who do not receive systemic treatment eventually experience destructive collapse of the femoral head cartilage and trabeculae, which will lead to joint dysfunction and joint damage within two to three years. Although prosthesis replacement can ultimately solve the patient's mobility problems in recent years, it has also greatly increased the medical costs of individuals and society and the corresponding complications caused by prosthesis replacement. Osteoblasts and osteoclasts affect the homeostasis of bone resorption and bone formation mediated by them through their biological activity and the interaction between the two, thereby regulating bone metabolism and playing a role in the occurrence and development of alcoholic femoral head necrosis. One of the early pathological manifestations of osteonecrosis in alcoholic femoral head necrosis is the reduction of bone formation caused by the large reduction of osteoblasts in bone tissue and the increase of osteoclast activity causing active bone resorption.
[0008] As one embodiment, the drug further contains a pharmaceutically acceptable salt or excipient of hemoglobin.
[0009] As one embodiment, the medicine is in the form of tablets, capsules or injections.
[0010] The beneficial effect of the present invention is that the hemoglobin of the present invention is the key active ingredient in the Tujia medicine hemoglobin. Existing studies have shown that hemoglobin has a significant effect of inhibiting the activity of fibroblast-like synoviocytes of rheumatoid arthritis, inhibiting the inflammatory factors produced by fibroblast-like synoviocytes of rheumatoid arthritis, and can inhibit the production of inflammatory factors by macrophages, inhibit the infiltration of inflammatory cells and synovial hyperplasia, and improve the symptoms of rheumatoid arthritis.
[0011] The present invention studies the pharmacodynamic effects and mechanisms of hemoglobin on bone destructive diseases. By focusing on the occurrence and mechanism of bone destruction and combining the RANKL-induced in vitro osteoclast model, the pharmacodynamic effects and mechanisms of hemoglobin on bone destruction are more comprehensively studied, which is conducive to in-depth exploration of the medicinal value of Tujia medicine hemoglobin. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1 shows the effect of hemoglobin on inhibiting osteoclast proliferation.
[0013] in, Figure 1A The effect of hemoglobin on osteoclast proliferation; Figure 1B The effect of hemoglobin on the activity of progenitor cells and osteoclasts; Figure 1C The effect of hemoglobin on different cell cycles of osteoclasts; Figure 1D For quantitative analysis of different cell cycle stages.
[0014] FIG. 2 shows that hemoglobin inhibits RANKL-induced osteoclast differentiation by inhibiting the RANKL / RANK pathway.
[0015] in, Figure 2A The effect of hemoglobin on osteoclast differentiation; Figure 2B For quantitative analysis of the number of osteoclasts in different groups; Figure 2C The effect of hemoglobin on the differentiation activity of osteoclasts; Figure 2D For the quantitative analysis of F-actin rings in different groups; Figure 2E The effect of hemoglobin on RANKL / RANK pathway proteins in osteoclasts; Figure 2F For quantitative analysis of protein gray value; Figure 2G The figure shows the effect of hemoglobin on the fluorescence expression of RANKL / RANK pathway proteins in osteoclasts.
[0016] FIG. 3 is a diagram showing the in vivo biosafety evaluation of hemoglobin.
[0017] in, Figure 3A The effect of hemoglobin on the bone resorption ability of osteoclasts; Figure 3B The effect of hemoglobin on bone resorption related proteins in osteoclasts; Figure 3C For quantitative analysis of protein gray value; Figure 3D The effect of hemoglobin on the fluorescence expression of bone resorption related proteins in osteoclasts. DETAILED DESCRIPTION
[0018] Example 1 Human RANKL factor was used to induce RAW264.7 cells to establish an in vitro osteoclast model and explore the effect of XTS on osteoclast differentiation. Rhodamine-phalloidin was used to stain the actin ring formed during osteoclast differentiation to evaluate the effect of XTS on actin ring formation. Western blotting and immunofluorescence were used to detect the levels of RANKL / RANK pathway-related proteins in osteoclasts treated with XTS.
[0019] The experimental results are shown in Figure 1.
[0020] Example 2 The survival rate of RAW264.7 cells induced / uninduced by RANKL treated with XTS was detected by MTT method, and the proliferation of osteoclasts treated with XTS was recorded in the form of pictures. The changes in the proportion of each cell cycle of osteoclasts treated with XTS were detected.
[0021] Bovine bone slices were used to detect the bone resorption ability of osteoclasts after XTS treatment. Western blotting and immunofluorescence were used to detect the levels of bone resorption-related proteins in osteoclasts after XTS treatment.
[0022] The experimental results are shown in Figures 2-3.
[0023] From Figures 1-3, it can be seen that hemoglobin has the use in treating bone destructive diseases.
[0024] A person skilled in the art should understand that the discussion of any of the above embodiments is merely illustrative and is not intended to imply that the scope of protection of the present application is limited to these examples. In line with the concept of the present application, the technical features in the above embodiments or different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of different aspects of one or more embodiments of the present application as described above, which are not provided in detail for the sake of simplicity.
[0025] One or more embodiments of the present application are intended to cover all such substitutions, modifications and variations that fall within the broad scope of the present application. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of one or more embodiments of the present application should be included in the protection scope of the present application.
Claims
1. A method for preparing a drug for treating bone destructive diseases.
2. The use according to claim 1, characterized in that: The bone destructive disease is alcoholic femoral head necrosis.
3. The use according to claim 1, characterized in that: The drug further contains a pharmaceutically acceptable salt or excipient of hemoglobin.
4. The use according to claim 1, characterized in that: The medicine is in the form of tablets, capsules or injections.
